Skip to main content
Erschienen in: Neuroradiology 11/2015

01.11.2015 | Diagnostic Neuroradiology

Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging

verfasst von: Leonard Sunwoo, Seung Hong Choi, Roh-Eul Yoo, Koung Mi Kang, Tae Jin Yun, Tae Min Kim, Se-Hoon Lee, Chul-Kee Park, Ji-hoon Kim, Sun-Won Park, Chul-Ho Sohn, Jae-Kyung Won, Sung-Hye Park, Il Han Kim

Erschienen in: Neuroradiology | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The aim of this study is to investigate perfusion characteristics of glioblastoma with an oligodendroglioma component (GBMO) compared with conventional glioblastoma (GBM) using dynamic susceptibility contrast (DSC) perfusion magnetic resonance (MR) imaging and microvessel density (MVD).

Methods

The study was approved by the institutional review board. Newly diagnosed high-grade glioma patients were enrolled (n = 72; 20 GBMs, 14 GBMOs, 19 anaplastic astrocytomas (AAs), 13 anaplastic oligodendrogliomas (AOs), and six anaplastic oligoastrocytomas (AOAs)). All participants underwent preoperative MR imaging including DSC perfusion MR imaging. Normalized cerebral blood volume (nCBV) values were analyzed using a histogram approach. Histogram parameters were subsequently compared across each tumor subtype and grade. MVD was quantified by immunohistochemistry staining and correlated with perfusion parameters. Progression-free survival (PFS) was assessed according to the tumor subtype.

Results

GBMO displayed significantly reduced nCBV values compared with GBM, whereas grade III tumors with oligodendroglial components (AO and AOA) exhibited significantly increased nCBV values compared with AA (p < 0.001). MVD analyses revealed the same pattern as nCBV results. In addition, a positive correlation between MVD and nCBV values was noted (r = 0.633, p < 0.001). Patients with oligodendroglial tumors exhibited significantly increased PFS compared with patients with pure astrocytomas in each grade.

Conclusion

In contrast to grade III tumors, the presence of oligodendroglial components in grade IV tumors resulted in paradoxically reduced perfusion metrics and MVD. In addition, patients with GBMO exhibited a better clinical outcome compared with patients with GBM.
Literatur
1.
Zurück zum Zitat Tortosa A, Vinolas N, Villa S, Verger E, Gil JM, Brell M, Caral L et al (2003) Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 97:1063–1071CrossRefPubMed Tortosa A, Vinolas N, Villa S, Verger E, Gil JM, Brell M, Caral L et al (2003) Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 97:1063–1071CrossRefPubMed
2.
Zurück zum Zitat Kanno H, Nishihara H, Narita T, Yamaguchi S, Kobayashi H, Tanino M, Kimura T et al (2012) Prognostic implication of histological oligodendroglial tumor component: clinicopathological analysis of 111 cases of malignant gliomas. PLoS One 7, e41669PubMedCentralCrossRefPubMed Kanno H, Nishihara H, Narita T, Yamaguchi S, Kobayashi H, Tanino M, Kimura T et al (2012) Prognostic implication of histological oligodendroglial tumor component: clinicopathological analysis of 111 cases of malignant gliomas. PLoS One 7, e41669PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat van den Bent M, Chinot OL, Cairncross JG (2003) Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro Oncol 5:128–138PubMedCentralPubMed van den Bent M, Chinot OL, Cairncross JG (2003) Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro Oncol 5:128–138PubMedCentralPubMed
4.
Zurück zum Zitat Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY (2012) Primary brain tumours in adults. Lancet 379:1984–1996CrossRefPubMed Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY (2012) Primary brain tumours in adults. Lancet 379:1984–1996CrossRefPubMed
5.
Zurück zum Zitat Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343PubMedCentralCrossRefPubMed Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350CrossRefPubMed van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350CrossRefPubMed
7.
Zurück zum Zitat Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCentralCrossRefPubMed Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Wang Y, Li S, Chen L, You G, Bao Z, Yan W, Shi Z et al (2012) Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol 14:518–525PubMedCentralCrossRefPubMed Wang Y, Li S, Chen L, You G, Bao Z, Yan W, Shi Z et al (2012) Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol 14:518–525PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Salvati M, Formichella AI, D’Elia A, Brogna C, Frati A, Giangaspero F, Delfini R et al (2009) Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases. J Neurooncol 94:129–134CrossRefPubMed Salvati M, Formichella AI, D’Elia A, Brogna C, Frati A, Giangaspero F, Delfini R et al (2009) Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases. J Neurooncol 94:129–134CrossRefPubMed
10.
Zurück zum Zitat Laxton RC, Popov S, Doey L, Jury A, Bhangoo R, Gullan R, Chandler C et al (2013) Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma. Neuro Oncol 15:1635–1643PubMedCentralCrossRefPubMed Laxton RC, Popov S, Doey L, Jury A, Bhangoo R, Gullan R, Chandler C et al (2013) Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma. Neuro Oncol 15:1635–1643PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Appin CL, Gao J, Chisolm C, Torian M, Alexis D, Vincentelli C, Schniederjan MJ et al (2013) Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics. Brain Pathol 23:454–461CrossRefPubMed Appin CL, Gao J, Chisolm C, Torian M, Alexis D, Vincentelli C, Schniederjan MJ et al (2013) Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics. Brain Pathol 23:454–461CrossRefPubMed
12.
Zurück zum Zitat Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GR, Fitzek MM et al (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 25:214–221PubMed Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GR, Fitzek MM et al (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 25:214–221PubMed
13.
Zurück zum Zitat Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ et al (2005) Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 26:266–273PubMed Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ et al (2005) Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 26:266–273PubMed
14.
Zurück zum Zitat Saito T, Yamasaki F, Kajiwara Y, Abe N, Akiyama Y, Kakuda T, Takeshima Y et al (2012) Role of perfusion-weighted imaging at 3T in the histopathological differentiation between astrocytic and oligodendroglial tumors. Eur J Radiol 81:1863–1869CrossRefPubMed Saito T, Yamasaki F, Kajiwara Y, Abe N, Akiyama Y, Kakuda T, Takeshima Y et al (2012) Role of perfusion-weighted imaging at 3T in the histopathological differentiation between astrocytic and oligodendroglial tumors. Eur J Radiol 81:1863–1869CrossRefPubMed
15.
Zurück zum Zitat Emblem KE, Scheie D, Due-Tonnessen P, Nedregaard B, Nome T, Hald JK, Beiske K et al (2008) Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes. AJNR Am J Neuroradiol 29:1664–1670CrossRefPubMed Emblem KE, Scheie D, Due-Tonnessen P, Nedregaard B, Nome T, Hald JK, Beiske K et al (2008) Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes. AJNR Am J Neuroradiol 29:1664–1670CrossRefPubMed
16.
Zurück zum Zitat Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972CrossRefPubMed Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972CrossRefPubMed
17.
Zurück zum Zitat Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR (1996) High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med 36:715–725CrossRefPubMed Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR (1996) High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med 36:715–725CrossRefPubMed
18.
Zurück zum Zitat Boxerman JL, Schmainda KM, Weisskoff RM (2006) Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 27:859–867PubMed Boxerman JL, Schmainda KM, Weisskoff RM (2006) Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 27:859–867PubMed
19.
Zurück zum Zitat Bjornerud A, Sorensen AG, Mouridsen K, Emblem KE (2011) T1- and T2*-dominant extravasation correction in DSC-MRI: part I—theoretical considerations and implications for assessment of tumor hemodynamic properties. J Cereb Blood Flow Metab 31:2041–2053PubMedCentralCrossRefPubMed Bjornerud A, Sorensen AG, Mouridsen K, Emblem KE (2011) T1- and T2*-dominant extravasation correction in DSC-MRI: part I—theoretical considerations and implications for assessment of tumor hemodynamic properties. J Cereb Blood Flow Metab 31:2041–2053PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Tozer DJ, Jager HR, Danchaivijitr N, Benton CE, Tofts PS, Rees JH, Waldman AD (2007) Apparent diffusion coefficient histograms may predict low-grade glioma subtype. NMR Biomed 20:49–57CrossRefPubMed Tozer DJ, Jager HR, Danchaivijitr N, Benton CE, Tofts PS, Rees JH, Waldman AD (2007) Apparent diffusion coefficient histograms may predict low-grade glioma subtype. NMR Biomed 20:49–57CrossRefPubMed
21.
Zurück zum Zitat Kang Y, Choi SH, Kim YJ, Kim KG, Sohn CH, Kim JH, Yun TJ et al (2011) Gliomas: Histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging—correlation with tumor grade. Radiology 261:882–890CrossRefPubMed Kang Y, Choi SH, Kim YJ, Kim KG, Sohn CH, Kim JH, Yun TJ et al (2011) Gliomas: Histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging—correlation with tumor grade. Radiology 261:882–890CrossRefPubMed
22.
Zurück zum Zitat Scheie D, Andresen PA, Cvancarova M, Bo AS, Helseth E, Skullerud K, Beiske K (2006) Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors. Am J Surg Pathol 30:828–837CrossRefPubMed Scheie D, Andresen PA, Cvancarova M, Bo AS, Helseth E, Skullerud K, Beiske K (2006) Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors. Am J Surg Pathol 30:828–837CrossRefPubMed
23.
Zurück zum Zitat Law M, Young RJ, Babb JS, Peccerelli N, Chheang S, Gruber ML, Miller DC et al (2008) Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247:490–498PubMedCentralCrossRefPubMed Law M, Young RJ, Babb JS, Peccerelli N, Chheang S, Gruber ML, Miller DC et al (2008) Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247:490–498PubMedCentralCrossRefPubMed
24.
Zurück zum Zitat Hirai T, Murakami R, Nakamura H, Kitajima M, Fukuoka H, Sasao A, Akter M et al (2008) Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol 29:1505–1510CrossRefPubMed Hirai T, Murakami R, Nakamura H, Kitajima M, Fukuoka H, Sasao A, Akter M et al (2008) Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol 29:1505–1510CrossRefPubMed
25.
Zurück zum Zitat Jain R, Poisson L, Narang J, Gutman D, Scarpace L, Hwang SN, Holder C et al (2013) Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology 267:212–220PubMedCentralCrossRefPubMed Jain R, Poisson L, Narang J, Gutman D, Scarpace L, Hwang SN, Holder C et al (2013) Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology 267:212–220PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479CrossRefPubMed Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479CrossRefPubMed
27.
Zurück zum Zitat Ren X, Cui X, Lin S, Wang J, Jiang Z, Sui D, Li J et al (2012) Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients. PLoS One 7, e32764PubMedCentralCrossRefPubMed Ren X, Cui X, Lin S, Wang J, Jiang Z, Sui D, Li J et al (2012) Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients. PLoS One 7, e32764PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Eoli M, Bissola L, Bruzzone MG, Pollo B, Maccagnano C, De Simone T, Valletta L et al (2006) Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer 119:84–90CrossRefPubMed Eoli M, Bissola L, Bruzzone MG, Pollo B, Maccagnano C, De Simone T, Valletta L et al (2006) Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer 119:84–90CrossRefPubMed
29.
Zurück zum Zitat Mizoguchi M, Yoshimoto K, Ma X, Guan Y, Hata N, Amano T, Nakamizo A et al (2012) Molecular characteristics of glioblastoma with 1p/19q co-deletion. Brain Tumor Pathol 29:148–153CrossRefPubMed Mizoguchi M, Yoshimoto K, Ma X, Guan Y, Hata N, Amano T, Nakamizo A et al (2012) Molecular characteristics of glioblastoma with 1p/19q co-deletion. Brain Tumor Pathol 29:148–153CrossRefPubMed
30.
Zurück zum Zitat He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S, Leuraud P et al (2001) Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 60:863–871PubMed He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S, Leuraud P et al (2001) Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 60:863–871PubMed
31.
Zurück zum Zitat Jenkinson MD, Smith TS, Joyce KA, Fildes D, Broome J, du Plessis DG, Haylock B et al (2006) Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 48:703–713PubMedCentralCrossRefPubMed Jenkinson MD, Smith TS, Joyce KA, Fildes D, Broome J, du Plessis DG, Haylock B et al (2006) Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 48:703–713PubMedCentralCrossRefPubMed
32.
33.
Zurück zum Zitat Ha SY, Kang SY, Do IG, Suh YL (2013) Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age. J Neurooncol 112:439–448CrossRefPubMed Ha SY, Kang SY, Do IG, Suh YL (2013) Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age. J Neurooncol 112:439–448CrossRefPubMed
34.
Zurück zum Zitat Labussiere M, Sanson M, Idbaih A, Delattre JY (2010) IDH1 gene mutations: a new paradigm in glioma prognosis and therapy? Oncologist 15:196–199PubMedCentralCrossRefPubMed Labussiere M, Sanson M, Idbaih A, Delattre JY (2010) IDH1 gene mutations: a new paradigm in glioma prognosis and therapy? Oncologist 15:196–199PubMedCentralCrossRefPubMed
35.
Zurück zum Zitat Sadeghi N, D’Haene N, Decaestecker C, Levivier M, Metens T, Maris C, Wikler D et al (2008) Apparent diffusion coefficient and cerebral blood volume in brain gliomas: relation to tumor cell density and tumor microvessel density based on stereotactic biopsies. AJNR Am J Neuroradiol 29:476–482CrossRefPubMed Sadeghi N, D’Haene N, Decaestecker C, Levivier M, Metens T, Maris C, Wikler D et al (2008) Apparent diffusion coefficient and cerebral blood volume in brain gliomas: relation to tumor cell density and tumor microvessel density based on stereotactic biopsies. AJNR Am J Neuroradiol 29:476–482CrossRefPubMed
36.
Zurück zum Zitat Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, Harsh GR et al (1994) Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191:41–51CrossRefPubMed Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, Harsh GR et al (1994) Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191:41–51CrossRefPubMed
37.
Zurück zum Zitat Cha S, Johnson G, Wadghiri YZ, Jin O, Babb J, Zagzag D, Turnbull DH (2003) Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med 49:848–855CrossRefPubMed Cha S, Johnson G, Wadghiri YZ, Jin O, Babb J, Zagzag D, Turnbull DH (2003) Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med 49:848–855CrossRefPubMed
38.
Zurück zum Zitat Jain R, Gutierrez J, Narang J, Scarpace L, Schultz LR, Lemke N, Patel SC et al (2011) In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas. AJNR Am J Neuroradiol 32:388–394CrossRefPubMed Jain R, Gutierrez J, Narang J, Scarpace L, Schultz LR, Lemke N, Patel SC et al (2011) In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas. AJNR Am J Neuroradiol 32:388–394CrossRefPubMed
Metadaten
Titel
Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging
verfasst von
Leonard Sunwoo
Seung Hong Choi
Roh-Eul Yoo
Koung Mi Kang
Tae Jin Yun
Tae Min Kim
Se-Hoon Lee
Chul-Kee Park
Ji-hoon Kim
Sun-Won Park
Chul-Ho Sohn
Jae-Kyung Won
Sung-Hye Park
Il Han Kim
Publikationsdatum
01.11.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Neuroradiology / Ausgabe 11/2015
Print ISSN: 0028-3940
Elektronische ISSN: 1432-1920
DOI
https://doi.org/10.1007/s00234-015-1569-6

Weitere Artikel der Ausgabe 11/2015

Neuroradiology 11/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.